Key Points
- Insider buying: Orchestra BioMed insider David Hochman bought 5,000 shares at an average price of $3.77, a transaction worth about $18,850. After the purchase, he owned just over 1.06 million shares.
- Recent earnings: The company reported a quarterly EPS of -$0.33, beating analyst expectations of -$0.40, but revenue came in well below estimates at $0.11 million versus $0.92 million expected.
- Wall Street view: Analysts remain cautiously bullish, with a consensus rating of Moderate Buy and an average price target of $13.60. Recent notes were mixed, including a Barclays upgrade to Overweight and a slight target cut from B. Riley.
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David Hochman acquired 5,000 shares of the business's stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $3.77 per share, for a total transaction of $18,850.00. Following the completion of the acquisition, the insider directly owned 1,059,029 shares of the company's stock, valued at approximately $3,992,539.33. This trade represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
Orchestra BioMed Stock Performance
OBIO opened at $4.00 on Wednesday. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average of $4.27 and a two-hundred day moving average of $4.27. Orchestra BioMed Holdings, Inc. has a 12-month low of $2.20 and a 12-month high of $5.42. The firm has a market capitalization of $239.52 million, a PE ratio of -4.12 and a beta of 0.52.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. On average, analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.54 EPS for the current year.
Institutional Investors Weigh In On Orchestra BioMed
Several large investors have recently added to or reduced their stakes in the business. Knott David M Jr lifted its holdings in Orchestra BioMed by 1.5% during the 1st quarter. Knott David M Jr now owns 253,651 shares of the company's stock worth $1,078,000 after buying an additional 3,651 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock valued at $134,000 after acquiring an additional 4,561 shares in the last quarter. Bank of America Corp DE boosted its holdings in Orchestra BioMed by 35.7% in the second quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock valued at $58,000 after purchasing an additional 5,678 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Orchestra BioMed during the 4th quarter worth about $38,000. Finally, Virtu Financial LLC acquired a new stake in Orchestra BioMed in the 4th quarter valued at about $57,000. 53.20% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages recently weighed in on OBIO. Barclays lifted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Wednesday, May 13th. Chardan Capital reissued a "buy" rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. B. Riley Financial lowered their price objective on Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Finally, Wall Street Zen cut Orchestra BioMed from a "hold" rating to a "sell" rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Orchestra BioMed has a consensus rating of "Moderate Buy" and an average target price of $13.60.
Get Our Latest Stock Report on OBIO
Trending Headlines about Orchestra BioMed
Here are the key news stories impacting Orchestra BioMed this week:
- Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by David P. Hochman and Jason Aryeh. Insider buying is often read as a vote of confidence in the company’s outlook. SEC filing for Eric Fain purchase
- Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while slightly raising near-term and FY2026 earnings estimates. That suggests analysts still see meaningful upside from current levels. Benzinga report
- Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which can raise visibility with investors and potential partners. Conference announcement
- Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating. The cut is a mild headwind, but the unchanged bullish rating limits the downside impact. Benzinga report
Orchestra BioMed Company Profile
(
Get Free Report)
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
